Results 151 to 160 of about 1,369,571 (283)

Early sodium‐glucose co‐transporter 2 inhibitor initiation is associated with improved cardiovascular outcomes in type 2 diabetes and acute coronary syndrome

Diabetic Medicine, EarlyView.
Abstract Aims Sodium‐glucose co‐transporter 2 inhibitors have demonstrated cardiovascular benefits in individuals with type 2 diabetes mellitus, but the optimal timing of initiation in those with acute coronary syndrome is not known. This study aims to assess if early therapy at discharge is superior to delayed or no therapy in reduction in major ...
Muhammad Usman Shah, Joanna Kate Ward, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee   +7 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Effects of mineralocorticoid receptor antagonists on coronary microcirculation: a mini-review. [PDF]

Front Cardiovasc Med
Li Y, Zhang Z.
europepmc   +1 more source

Kidney Outcomes With GLP‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To compare kidney outcomes after GLP‐1 receptor agonists (RA) or tirzepatide (GLP‐1/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD). Methods In a retrospective TriNetX global network study (July 2021–November 2025), adults with T2D and CKD stages 3–4 initiating GLP‐1/GIP ...
Dvora R. Sehtman‐Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel   +5 more
wiley   +1 more source

Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial‐Eligible and Ineligible Populations: A DEVOTE‐Inspired Target Trial Emulation Using the Swedish National Diabetes Register

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods We conducted a nationwide observational cohort study using Swedish health registers, including the National Diabetes Register ...
Thomas Nyström, Jens Michelsen, Henrik Imberg, Sara Hallström, Viktor Tasselius, Anna Norhammar, Max Petzold, Julia K. Mader, Pratik Choudhary, Manal K. Elzalabany, Jonathan Valabhji, Shivani Misra, Safoora Gharibzadeh, Puriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Christian Torp‐Pedersen, Marcus Lind   +16 more
wiley   +1 more source

Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD. [PDF]

Kidney Int Rep
Korucu B, Colak A, Mustafa R, Earley A, Wheeler DC.   +4 more
europepmc   +1 more source

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, EarlyView.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure. [PDF]

JACC Adv
Michos ED, Ambrosy AP, Fonarow GC.
europepmc   +1 more source